clinical trial · NCT05780879
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
University of Michigan Rogel Cancer Center·phase2·terminated·n = 10
Secondary Acute Myeloid LeukemiaVenetoclaxFLAG or CLAG Protocol
brief summary
The primary purpose of this study is to determine complete remission rate of a novel combination induction chemotherapy treatment based upon 20 patients with newly diagnosed secondary AML.
started
Jun 3, 2024
primary completion
Aug 16, 2025
completion
Aug 16, 2025
last updated
Aug 24, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol